Trials / Completed
CompletedNCT00110864
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Wellstat Therapeutics · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of PN2034 in insulin-dependent type 2 diabetics as measured by the change in average daily insulin dose from baseline to week 12. The effects of PN2034 on HbA1c, fasting plasma glucose (FPG), and lipid levels will also be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PN2034 | |
| DRUG | Insulin |
Timeline
- Start date
- 2005-05-01
- Completion
- 2007-04-01
- First posted
- 2005-05-16
- Last updated
- 2007-08-23
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00110864. Inclusion in this directory is not an endorsement.